Jacob K Kresovich1, Peter H Gann1,2, Serap Erdal3, Hua Y Chen1, Maria Argos1, Garth H Rauscher1. 1. Division of Epidemiology & Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA. 2. Department of Pathology, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA. 3. Division of Environmental & Occupational Health Sciences, University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA.
Abstract
AIM: We examined methylation patterns with aggressive tumor phenotypes and investigated demographic, socioeconomic and reproductive predictors of gene methylation. MATERIALS & METHODS: Pyrosequencing quantified methylation of BRCA1, EGFR, GSTM2, RASSF1, TFF1 and Sat 2. We used quantile regression models to calculate adjusted median methylation values by estrogen and progesterone receptor (ER/PR) status. Bivariate associations between participant characteristics and methylation were examined. RESULTS: Higher percent methylation of GSTM2 was observed in ER/PR-negative compared with ER/PR-positive tumors in ductal carcinoma in situ (14 vs 2%) and invasive (35 vs 3%) tissue components. Trends in aberrant GSTM2 methylation across tissue components were stronger among ER/PR-negative tumors (p-interaction <0.001). Black women were more likely to have ER/PR-negative tumors (p = 0.01) and show hypermethylation of GSTM2 compared with other women (p = 0.05). CONCLUSION: GSTM2 promoter hypermethylation may serve as a potential biomarker of aggressive tumor development and a mechanism for ER/PR-negative tumor progression.
AIM: We examined methylation patterns with aggressive tumor phenotypes and investigated demographic, socioeconomic and reproductive predictors of gene methylation. MATERIALS & METHODS: Pyrosequencing quantified methylation of BRCA1, EGFR, GSTM2, RASSF1, TFF1 and Sat 2. We used quantile regression models to calculate adjusted median methylation values by estrogen and progesterone receptor (ER/PR) status. Bivariate associations between participant characteristics and methylation were examined. RESULTS: Higher percent methylation of GSTM2 was observed in ER/PR-negative compared with ER/PR-positive tumors in ductal carcinoma in situ (14 vs 2%) and invasive (35 vs 3%) tissue components. Trends in aberrant GSTM2 methylation across tissue components were stronger among ER/PR-negative tumors (p-interaction <0.001). Black women were more likely to have ER/PR-negative tumors (p = 0.01) and show hypermethylation of GSTM2 compared with other women (p = 0.05). CONCLUSION:GSTM2 promoter hypermethylation may serve as a potential biomarker of aggressive tumor development and a mechanism for ER/PR-negative tumor progression.
Entities:
Keywords:
DNA methylation; GSTM2; breast cancer; breast cancer disparities; estrogen/progesterone receptor; tumor progression
Authors: Catherine L Callahan; Youjin Wang; Catalin Marian; Daniel Y Weng; Kevin H Eng; Meng-Hua Tao; Christine B Ambrosone; Jing Nie; Maurizio Trevisan; Dominic Smiraglia; Stephen B Edge; Peter G Shields; Jo L Freudenheim Journal: Epigenetics Date: 2016-05-31 Impact factor: 4.528
Authors: M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman Journal: J Natl Cancer Inst Date: 2000-04-05 Impact factor: 13.506
Authors: Benjamin P Berman; Daniel J Weisenberger; Joseph F Aman; Toshinori Hinoue; Zachary Ramjan; Yaping Liu; Houtan Noushmehr; Christopher P E Lange; Cornelis M van Dijk; Rob A E M Tollenaar; David Van Den Berg; Peter W Laird Journal: Nat Genet Date: 2011-11-27 Impact factor: 38.330
Authors: Mary Jo Fackler; Christopher B Umbricht; Danielle Williams; Pedram Argani; Leigh-Ann Cruz; Vanessa F Merino; Wei Wen Teo; Zhe Zhang; Peng Huang; Kala Visvananthan; Jeffrey Marks; Stephen Ethier; Joe W Gray; Antonio C Wolff; Leslie M Cope; Saraswati Sukumar Journal: Cancer Res Date: 2011-08-08 Impact factor: 12.701
Authors: Garth H Rauscher; Jacob K Kresovich; Matthew Poulin; Liying Yan; Virgilia Macias; Abeer M Mahmoud; Umaima Al-Alem; Andre Kajdacsy-Balla; Elizabeth L Wiley; Debra Tonetti; Melanie Ehrlich Journal: BMC Cancer Date: 2015-10-29 Impact factor: 4.430
Authors: Kevin C Johnson; Devin C Koestler; Thomas Fleischer; Panpan Chen; Erik G Jenson; Jonathan D Marotti; Tracy Onega; Vessela N Kristensen; Brock C Christensen Journal: Clin Epigenetics Date: 2015-07-25 Impact factor: 6.551
Authors: Elgilda Musi; Gary K Schwartz; Jae Hyuk Yoo; Shannon J Odelberg; Dean Y Li; Michael Y Bonner; Ponniah Selvakumar; Shikha Rao; Linda C Gilbert; Justin Elsey; Jack L Arbiser Journal: Oncotarget Date: 2019-07-08